Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiotensin II receptor subtypes.

P B Timmermans1, A T Chiu, W F Herblin

  • 1Du Pont Merck Pharmaceutical Company, Wilmington, DE 19880-0400.

American Journal of Hypertension
|June 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacological properties of angiotensin II receptor antagonists.

The Canadian journal of cardiology·1999
Same author

Combined spinal-epidural analgesia in the management of labouring parturients with mitral stenosis.

Anaesthesia and intensive care·1999
Same author

Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics.

Hypertension research : official journal of the Japanese Society of Hypertension·1999
Same author

Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors.

Proceedings of the National Academy of Sciences of the United States of America·1999
Same author

Rationale, background, and design of the randomized angiotensin receptor antagonist--angiotensin-converting enzyme inhibitor study (RAAS).

The American journal of cardiology·1996
Same author

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.

Journal of medicinal chemistry·1996
Same journal

ADAM17 as a promising molecular target for organ protection in antihypertensive therapy.

American journal of hypertension·2026
Same journal

Efficacy and Safety of Baxdrostat in the Management of Uncontrolled Hypertension: A Systematic Review and Meta-Analysis.

American journal of hypertension·2026
Same journal

Hemodynamic Evolution of Heart Failure from Hypertension: Lower Stroke Volume Index and Higher Heart Rate.

American journal of hypertension·2026
Same journal

Opposite Seasonal Variation in Nighttime and Morning Blood Pressure: A Longitudinal Study of Patients with Hypertension.

American journal of hypertension·2026
Same journal

Screening for Postprandial Hypotension: The Importance of Home Blood Pressure Monitoring.

American journal of hypertension·2026
Same journal

Distinct Mediating Roles of Hypertension in Arterial Stiffness Mechanisms Associated with Cardiovascular Disease Risk: A Community-Based Cohort Study.

American journal of hypertension·2026
See all related articles

Angiotensin II (Ang II) receptors have subtypes, AT1 and AT2. AT1 receptors mediate major Ang II effects like vasoconstriction, while AT2 receptor functions remain unclear.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Cardiovascular Science

Background:

  • Angiotensin II (Ang II) is a key peptide hormone in the renin-angiotensin system.
  • Ang II exerts diverse physiological effects by binding to specific cell surface receptors.
  • Evidence for Ang II receptor heterogeneity has been established through novel antagonists.

Purpose of the Study:

  • To provide definitive evidence for Angiotensin II (Ang II) receptor subtypes.
  • To characterize the binding affinities of new nonpeptide Ang II receptor antagonists.
  • To investigate the distribution and functional roles of identified Ang II receptor subtypes.

Main Methods:

  • Utilized nonpeptide Ang II receptor antagonists, DuP 753 and PD 123177, to differentiate receptor subtypes.

Related Experiment Videos

  • Assessed receptor binding affinities for various Ang II analogs and antagonists.
  • Examined the tissue distribution of AT1 and AT2 receptors across different species and organs.

    • Main Results:

    • Identified two distinct Ang II receptor binding sites: AT1 (high affinity for DuP 753) and AT2 (high affinity for PD 123177).
    • Demonstrated that AT1 receptors mediate major Ang II effects, including vasoconstriction and hormone secretion.
    • Observed widespread occurrence of both AT1 and AT2 receptors, with significant variations in their proportions across tissues and species.

    Conclusions:

    • Angiotensin II (Ang II) receptor heterogeneity is confirmed, with distinct AT1 and AT2 subtypes.
    • The AT1 receptor subtype is responsible for mediating the primary biological actions of Ang II.
    • The functional significance of the abundant AT2 receptor subtype requires further investigation.